A groundbreaking study conducted by Oxford University researchers and published in the journal npj Vaccines has uncovered an intriguing link between certain vaccines and a reduced risk of developing dementia. Analyzing data from over 130,000 US residents, the researchers found that vaccinations with Shingrix (for shingles) and Arexyv (for respiratory syncytial virus) were associated with a notably lower dementia risk compared to the standard flu shot.
Both Shingrix and Arexyv vaccines incorporate a specific adjuvant – a component designed to amplify the body`s immune response, making it more robust and long-lasting. Scientists hypothesize that this immune-boosting adjuvant might trigger protective mechanisms that positively influence the brain`s cognitive functions.
The findings indicated that within 18 months following Shingrix vaccination, the risk of dementia decreased by 18%, and after Arexyv vaccination, it dropped by 29%. For individuals who received both immunizations, the risk reduction was an impressive 37%. Notably, this protective effect manifested too rapidly to be solely attributed to protection against the viral infections themselves, suggesting another mode of action for these vaccines within the body.
Researchers believe that the observed effect could be linked to the vaccines` impact on the brain`s immune system. A growing body of scientific literature increasingly emphasizes that cognitive impairment and memory issues are not solely dependent on neuronal damage but also on the state of the immune system. These new findings offer hope that certain vaccines could not only prevent infections but also contribute to maintaining cognitive clarity in older age.
In a related discovery concerning the alleviation of dementia symptoms, it was previously noted that integrating music into the daily care routine for patients can help reduce stress and disorientation, thereby enhancing their overall quality of life.
